Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02576 太美醫療科技
TAIMEI TECH
Listing Date2024/10/08
Listing Price13.000
 
Quote
  • 5.170 -0.140 (-2.637%)    Sink Below Listing Price
  • 15-min delayed, last update: 15/11/2024 12:40
Subscription Result
  • Subscription Rate
    156.33x
  • Guarantee One Lot Size
    40 lot
  • One Lot Success Rate
    2.69%
COMPANY PROFILE

Zhejiang Taimei Medical Technology Co is a digital solution provider focused on the pharmaceutical and medical device industry in China. It designs and delivers industry-specific software and digital services that facilitates the research and development as well as commercialization of pharmaceuticals and medical devices.

--

The Group’s solutions for the pharmaceutical and medical device industry consist of cloud-based software, including SaaS products and customized products, and digital services. Its SaaS products and digital services are primarily offered through digital collaboration platforms, including TrialOS and PharmaOS.

--

The Group is the largest digital solution provider for pharmaceutical and medical device R&D and commercialization in China in terms of revenue in 2023, taking up a market share of 5.9%, according to CIC. As of March 31, 2024, it had served over 1,400 pharmaceutical companies and contract research organizations, including 21 out of the top 25 global pharmaceutical companies and 90 of the top 100 Chinese pharmaceutical innovators.

--

The Group’s customers mainly included pharmaceutical and medical device companies, third-party service providers (e.g. CROs), clinical research institutions and others.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot200
GLOBAL OFFERING
No. of Offer Shares25.78M H shares
No. of International Offer Shares12.89M H shares
No. of HK Offer Shares12.89M H shares
Offer Price$10.00 - $13.00
Stock Code2576
Sponsor(s)Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited
Underwriter(s)Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited, CMB International Capital Limited, CCB International Capital Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Valuable Capital Limited
TIME TABLE
Application PeriodSep 27 (Fri) - noon, Oct 03 (Thu)
Price Determination DateOct 04 (Fri)
Result Announcement DateOn or before Oct 07 (Mon)
Result Announcement DateOn or before Oct 07 (Mon)
Result Announcement DateOn or before Oct 08 (Tue)
Dealings in Shares commence onOct 08, 2024. (Tue)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$10.00 - $13.00
Capitalization (H Shares)1.97B - 2.56B
NAV / share ($)$2.02 - $2.13 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 11.5, the net proceeds raised would be HKD 185.70M, of which
35% : Improve and upgrade TrialOS Platform and PharmaOS Platform and their respective cloud-based software and digital services
30% : Improve core technology and R&D capabilities
10% : Strengthen sales and marketing capabilities
15% : Pursue strategic investments and acquisitions to expand existing product and service offerings, expand customer base and enhance technology capabilities
10% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
:
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.